Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended rituximab treatment vs placebo in resistant rheumatoid arthritis
2006-005640-81Phase 3Terminated
- Sponsor
- University of Leeds
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Extended rituximab (three-dose) group with Standard rituximab plus placebo group (2 arms). Primary endpoint: ACR20 response at Week 28. Started Jul 2007; status: terminated.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-005640-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005640-81.